Abzena : Result of Annual General Meeting

Abzena plc

Result of Annual General Meeting

Cambridge, UK, 17 September 2018:Abzena plc (AIM: ABZA, 'Abzena' or the 'Group'), the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, announces that at its Annual General Meeting held today at 10:00am at the offices of Pinsent Masons LLP, 30 Crown Place, Earl Street, London, EC2A 4ES, all resolutions were duly passed.

Details of the votes received in relation to each of the resolutions are as follows:

Resol	Vote For	% In favour	Votes Against	% Against	Votes Abstain	% Abstain	Total Votes
1	122,288,284	100	0	0	0	0	122,288,284
2	122,288,284	100	0	0	0	0	122,288,284
3	122,288,284	100	0	0	0	0	122,288,284
4	122,288,284	100	0	0	0	0	122,288,284
5	122,288,284	100	0	0	0	0	122,288,284
6	122,288,284	100	0	0	0	0	122,288,284
7	122,288,284	100	0	0	0	0	122,288,284
8	122,288,284	100	0	0	0	0	122,288,284

Percentage figures have been subject to rounding as considered appropriate.

The total number of ordinary shares of £0.002 each eligible to be voted at the Annual General Meeting was 214,220,399.

Enquiries:

Abzena Plc John Burt(Chief Executive Officer) Julian Smith(Chief Financial Officer)	[phone]
N+1 Singer(Nominated Adviser and Broker) Aubrey Powell Ben Farrow	[phone]
Instinctif Partners Melanie Toyne Sewell Rozi Morris Alex Shaw	[phone] [e-mail]

Notes to Editors

Abzena (AIM: ABZA) provides proprietary technologies and complementary services to enable the development and manufacture of biopharmaceutical products.

The term 'ABZENAInside' is used by Abzena to describe products that have been created using its proprietary technologies and are being developed by its partners, and include Composite Human Antibodies™ and ThioBridge™ Antibody Drug Conjugates (ADCs). Abzena has the potential to earn future licence fees, milestone payments and/or royalties on ABZENAInside products.

Abzena offers the following services and technologies across its principal sites in Cambridge (UK), San Diego, California (USA) and Bristol, Pennsylvania (USA):

· Biology research studies, including immunogenicity assessment of candidate biopharmaceutical products and bioassay development;

· Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;

· Cell line development for the manufacture of recombinant proteins and antibodies;

· Contract process development and GMP manufacture of biopharmaceuticals, including monoclonal antibodies and recombinant proteins for preclinical and clinical studies;

· Contract synthetic chemistry and bioconjugation research services, focused on antibody-drug conjugates (ADCs);

· Proprietary site-specific conjugation technologies and novel payloads for ADC development;

· GMP manufacturing of ADC linkers, payloads & combined linker-payloads; and

· GMP analytical services for biopharmaceutical manufacturing projects.

For more information, please see www.abzena.com.